Home Featured Page 217

Featured

Latest

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Weekly Psychedelic Policy Briefing: August 23, 2026

Field Notes #4: Resilient Refiles, Definium’s Readout, HRSA’s RFI Responses, and J&J’s Neuroplastogen Bet

Weekly Psychedelic Policy Briefing – August 16, 2026

Psychedelic Bulletin: COMPASS’ “Infamous” Psilocybin Patent Challenged; atai Stock Price Tumbles...

MYND Life Sciences Acquires Rights for the Use of Psychedelics to...

PTSF89 – A Macro Dive Into Microdosing

MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult...

COMPASS Selected for Addition to NASDAQ Biotechnology Index

Entheon Biomedical Announces EEG Patent Application & Provides Research Update

MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent...

Psychedelics and Substance Use Disorder: 4000 BCE to Present Day

Psyched Wellness Announces Path to Market for AME-1-derived Products in the...

COMPASS Pathways announces changes in Executive Team

EDITOR PICKS

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Weekly Psychedelic Policy Briefing: August 23, 2026

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Who Gets to Heal?

Weekly Psychedelic Policy Briefing: August 23, 2026

Field Notes #4: Resilient Refiles, Definium’s Readout, HRSA’s RFI Responses, and J&J’s Neuroplastogen Bet

Weekly Psychedelic Policy Briefing – August 16, 2026

Psychedelic Bulletin: COMPASS’ “Infamous” Psilocybin Patent Challenged; atai Stock Price Tumbles...

MYND Life Sciences Acquires Rights for the Use of Psychedelics to...

PTSF89 – A Macro Dive Into Microdosing

MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult...

COMPASS Selected for Addition to NASDAQ Biotechnology Index

Entheon Biomedical Announces EEG Patent Application & Provides Research Update

MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent...

Psychedelics and Substance Use Disorder: 4000 BCE to Present Day

Psyched Wellness Announces Path to Market for AME-1-derived Products in the...

COMPASS Pathways announces changes in Executive Team

EDITOR PICKS

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Who Gets to Heal?

Weekly Psychedelic Policy Briefing: August 23, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY